MSB 0.00% 99.5¢ mesoblast limited

Ann: MSB Completes Financing For Covid-19 ARDS Manufacturing, page-33

  1. 2,124 Posts.
    lightbulb Created with Sketch. 45
    the Company’s lead product
    candidate remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine
    release syndromes associated with high mortality, particularly COVID-19 acute respiratory distress syndrome
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.